Personal CFO Solutions LLC Increases Position in Danaher Co. (NYSE:DHR)

Personal CFO Solutions LLC increased its stake in Danaher Co. (NYSE:DHR) by 5.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,925 shares of the conglomerate’s stock after purchasing an additional 156 shares during the quarter. Personal CFO Solutions LLC’s holdings in Danaher were worth $677,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in DHR. Security National Bank purchased a new position in Danaher during the 4th quarter valued at about $164,000. Tsai Capital Corp increased its holdings in Danaher by 14.2% during the 4th quarter. Tsai Capital Corp now owns 12,761 shares of the conglomerate’s stock valued at $2,952,000 after acquiring an additional 1,587 shares in the last quarter. Westwood Holdings Group Inc. increased its holdings in Danaher by 7.8% during the 4th quarter. Westwood Holdings Group Inc. now owns 351,379 shares of the conglomerate’s stock valued at $81,288,000 after acquiring an additional 25,411 shares in the last quarter. Waterloo Capital L.P. purchased a new position in Danaher during the 4th quarter valued at about $1,068,000. Finally, RTW Investments LP purchased a new position in Danaher during the 4th quarter valued at about $27,433,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.8 %

DHR stock traded down $4.90 during midday trading on Friday, reaching $263.08. 3,626,851 shares of the company’s stock traded hands, compared to its average volume of 2,631,043. The company has a market capitalization of $194.86 billion, a P/E ratio of 44.59, a PEG ratio of 4.02 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The business has a 50-day moving average price of $251.96 and a two-hundred day moving average price of $242.92.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.36 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Analyst Ratings Changes

Several research firms have weighed in on DHR. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their price target for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, Robert W. Baird raised their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $269.29.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the sale, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.